CD278/ICOS
Alpha Lifetech can provide CD278/ICOS corresponding products, help each customer's research and development.
01
Introduction To CD278/ICOS
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD278/ICOS protein is a common target in medicine.
The inducible costimulatory factor (inducible co-stimulator, ICOS), also known as CD278, was identified in 1999. It is a member of the immunoglobulin superfamily. It is the receptor of B7-H2 (CD275) molecules in the B7 family, which is expressed on the surface of activated T cells, and B7-H2 binds to ICOS to mediate the costimulatory signal of T cells, thus causing hyperplasia of T cells.
Function of Target CD278/ICOS
ICOS induces cell proliferation, survival, and differentiation and regulates various T cell functions, including activation of CD8 + effector T cells, interaction with B cells, and infiltration of regulatory T cells. Studies on tumorigenesis and tumor therapy show that ICOS is a potential target with bidirectional behavior, enhancing the anti-tumor T cell killing on the one hand and assisting tumor initiation and development through Treg cells on the other hand. However, both ICOS synergistic and antagonistic antibodies can act as molecules for targeted therapy in the ICOS / ICOSL signaling pathway for antitumor therapy, ICOS activation may enhance the effect of immune checkpoint blocking, and can also reduce the immunosuppressive effect of T reg cells and inhibit the expression of TFH markers in lymphoma cells.
Gene Pathway of Target CD278/ICOS
The CD275-CD278 costimulatory pathway is the pathway of the CD28-B7 family molecules involved in the effector phase of the T cell-mediated immune response. ICOS / ICOSL signaling pathway has dual effects, on the one hand, costimulatory signals of ICOS / ICOSL can promote tumorigenesis, and on the other hand, ICOS signaling also has antitumor effects.ICOS transmits signals mainly by interacting with CD275. After CD275 binds to ICOS, it may initiate the phosphorylation of Akt (protein kinase B) by activating PI3K (phosphatidylinositol 3-kinase), which then activates the mTOR (mammalian target of rapamycin) signaling pathway to promote the proliferation and survival of T cells. ICOS signaling may also be transmitted through members of the JAK (Janus kinase) and STAT (signal transducers and transcriptional activator) families, affecting the differentiation and function of T cells.
Fig 1: ICOS Gene Pathway. (Reference source: Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020 Jan;5(1):e000544.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD278/ICOS are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD278/ICOS protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD278/ICOS protein products are also essential. Alpha Lifetech can provide CD278/ICOS corresponding products and help each customer's research and development. In addition, Alpha Lifetech can provide recombinant proteins and Biosimilar antibody products. The effectiveness of the products has been verified through spot products, and we also provide corresponding customized services to help our client companies efficiently and accurately screen corresponding targets through efficient and accurate EC50/IC50. At the same time, Alpha Lifetech also provides services such as recombinant antibody production, recombinant protein production, antibody and protein purification, and affinity verification to ensure the maturity of recombinant antibody affinity and assist customers in antibody drug discovery and subsequent experiments.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64680 | 50ug,100ug,500ug | |
| ALP64584 | 50ug,100ug,500ug | |
Reference
[1] Ansari AW, Ahmad F, Rasheed T, Jochebeth A, Mateo JMP, Abdulrahman N, Joy EF, Alam MA, Buddenkotte J, Hamoudi RA, Steinhoff M. Azithromycin downregulates ICOS (CD278) and OX40 (CD134) expression and mTOR activity of TCR-activated T cells to inhibit proliferation. Int Immunopharmacol. 2023 Nov;124(Pt A):110831.
[2] Zhao X, Wang Y, Jiang X, Mo B, Wang C, Tang M, Rong Y, Zhang G, Hu M, Cai H. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy. BMC Cancer. 2023 Feb 28;23(1):194.
[3] Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020 Jan;5(1):e000544.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102